Literature DB >> 20722590

Current treatments for radiation retinopathy.

Gian Paolo Giuliari1, Ama Sadaka, David M Hinkle, E Rand Simpson.   

Abstract

BACKGROUND: to review the currently available therapeutic modalities for radiation retinopathy (RR), including newer investigational interventions directed towards specific aspects of the pathophysiology of this refractory complication.
METHODS: a review of the literature encompassing the pathogenesis of RR and the current therapeutic modalities available was performed.
RESULTS: RR is a chronic and progressive condition that results from exposure to any source of radiation. It might be secondary to radiation treatment of intraocular tumors such as choroidal melanomas, retinoblastomas, and choroidal metastasis, or from unavoidable exposure to excessive radiation from the treatment of extraocular tumors like cephalic, nasopharyngeal, orbital, and paranasal malignancies. After the results of the Collaborative Ocular Melanoma Study, most of the choroidal melanomas are being treated with plaque brachytherapy increasing by that the incidence of this radiation complication. RR has been reported to occur in as many as 60% of eyes treated with plaque radiation, with higher rates associated with larger tumors. Initially, the condition manifests as a radiation vasculopathy clinically seen as microaneurysms and telangiectases, with posterior development of retinal hard exudates and hemorrhages, macular edema, neovascularization and tractional retinal detachment. Regrettably, the management of these eyes remains limited. Photodynamic therapy, laser photocoagulation, oral pentoxyphylline and hyperbaric oxygen have been attempted as treatment modalities with inconclusive results. Intravitreal injections of anti-vascular endothelial growth factor such as bevacizumab, ranibizumab and pegaptanib sodium have been recently used, also with variable results. DISCUSSION: RR is a common vision threatening complication following radiation therapy. The available therapeutic options are limited and show unsatisfactory results. Further large investigative studies are required for developing better therapeutic as well as preventive treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20722590     DOI: 10.3109/0284186X.2010.500299

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  20 in total

1.  [Vitreous hemorrhage of unusual genesis].

Authors:  M Lukashevich; C Mayer
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

2.  Radiation retinopathy treated successfully with aflibercept.

Authors:  Pakinee Pooprasert; Tafadzwa Young-Zvandasara; Ayad Al-Bermani
Journal:  BMJ Case Rep       Date:  2017-11-09

3.  Bevacizumab in vitreous haemorrhage secondary to radiation retinopathy.

Authors:  Javier Antonio Montero; Giovanni Yanez-Castro; Maria Eugenia Sanchis-Merino; Jose Maria Ruiz-Moreno
Journal:  BMJ Case Rep       Date:  2014-02-07

4.  Longitudinal Detection of Radiation-Induced Peripapillary and Macular Retinal Capillary Ischemia Using OCT Angiography.

Authors:  Alison H Skalet; Liang Liu; Christina Binder; Audra K Miller; Richard Crilly; Arthur Y Hung; David J Wilson; David Huang; Yali Jia
Journal:  Ophthalmol Retina       Date:  2019-10-11

Review 5.  Effects of radiotherapy on uveal melanomas and adjacent tissues.

Authors:  C Groenewald; L Konstantinidis; B Damato
Journal:  Eye (Lond)       Date:  2012-11-30       Impact factor: 3.775

6.  The Use of Intravitreal Anti-VEGF and Triamcinolone in the Treatment of Radiation Papillopathy.

Authors:  Kelsey Roelofs; Matthew P Larocque; Albert Murtha; Ezekiel Weis
Journal:  Ocul Oncol Pathol       Date:  2018-06-08

7.  Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.

Authors:  Katsuyuki Shirai; Michael R Siedow; Arnab Chakravarti
Journal:  J Oncol       Date:  2011-07-14       Impact factor: 4.375

8.  Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity.

Authors:  Nisha V Shah; Samuel K Houston; Arnold M Markoe; William Feuer; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2012-10-29

9.  Early reduction of microglia activation by irradiation in a model of chronic glaucoma.

Authors:  Alejandra Bosco; Samuel D Crish; Michael R Steele; Cesar O Romero; Denise M Inman; Philip J Horner; David J Calkins; Monica L Vetter
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

10.  Bilateral episcleral brachytherapy in simultaneous choroidal melanoma and circumscribed hemangioma.

Authors:  María Encarnación Correa-Pérez; María Antonia Saornil; Ciro García-Álvarez; Francisco Lopez-Lara Martín; Jesus María Frutos-Baraja
Journal:  J Contemp Brachytherapy       Date:  2013-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.